The open-session hearing comes just weeks ahead of the agency’s Aug. 5 target date to decide on the vaccine’s approval. ・In ...

Moderna’s experimental mRNA flu shot will be reviewed by a Food and Drug Administration (FDA) advisory panel next month, a move that suggests a more stable approach to drug reviews after the firing of ...

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

Engineers from the University of Houston, MIT and Harvard have developed a new mRNA-based strategy that dramatically amplifies the T-cell response to vaccines - an advance that could lead to far more ...

WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and ...

Vaccines using mRNA technology weren’t immune to the latest round of federal research cuts. Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he’s pulling the plug on ...

I n December 2020, mRNA vaccines leapt into the limelight as a response to the COVID-19 pandemic. To date, millions of people ...

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study by researchers at University of Pittsburgh School of Public ...

Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and ...

In the first quarter of 2026, Moderna reported revenue of US$389 million versus US$108 million a year earlier, while net loss widened to US$1.34 billion, largely reflecting a US$950 million litigation ...